Business Context and Reporting Period
This Form 8-K is a current report filed by TransDel Pharmaceuticals, Inc. (not Harrow, Inc.) on April 20, 2011, covering events occurring on April 14, 2011. The registrant is incorporated in Delaware with principal executive offices in La Jolla, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
Effective April 14, 2011, Lynn C. Swann resigned from the Company's Board of Directors. The filing explicitly states that the resignation was not in connection with any known disagreement with the Company on any matter.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the director departure.
Investor Verification Checklist
- Verify the identity of the registrant as TransDel Pharmaceuticals, Inc., noting the discrepancy with the requested company name "Harrow, Inc."
- Confirm the effective date of Lynn C. Swann's resignation (April 14, 2011).
- Review subsequent filings to determine if a replacement director was appointed.